• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2023 年秋季 COVID-19 疫苗对基于医院的医护人员的有效性:VEBIS 医护人员疫苗有效性队列研究的结果,七个欧洲国家,2023/24 年季节。

Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24.

机构信息

Epiconcept, Paris, France.

These authors contributed equally to this work and share first authorship. The other co-authors are listed in the alphabetical order of their countries.

出版信息

Euro Surveill. 2024 Oct;29(44). doi: 10.2807/1560-7917.ES.2024.29.44.2400680.

DOI:10.2807/1560-7917.ES.2024.29.44.2400680
PMID:39484687
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11528902/
Abstract

COVID-19 vaccination recommendations include healthcare workers (HCWs). We measured COVID-19 vaccine effectiveness (CVE) of the autumn 2023 dose against laboratory-confirmed SARS-CoV-2 infection in a prospective cohort study of 1,305 HCWs from 13 European hospitals. Overall CVE was 22% (95% CI: -17 to 48), 49% (95% CI: -8 to 76) before and -11% (95% CI: -84 to 34) after the start of BA.2.86/JN.1 predominant circulation. Autumn 2023 COVID-19 vaccination led to a moderate-to-low reduction in SARS-CoV-2 infection incidence in HCWs. Monitoring of CVE is crucial for COVID-19 prevention.

摘要

COVID-19 疫苗接种建议包括医护人员(HCWs)。我们在一项针对来自欧洲 13 家医院的 1305 名 HCWs 的前瞻性队列研究中,测量了 2023 年秋季剂量对实验室确诊的 SARS-CoV-2 感染的 COVID-19 疫苗有效性(CVE)。总体 CVE 为 22%(95%CI:-17%至 48%),在 BA.2.86/JN.1 占主导地位之前为 49%(95%CI:-8%至 76%),之后为-11%(95%CI:-84%至 34%)循环。2023 年秋季 COVID-19 疫苗接种导致 HCWs 中 SARS-CoV-2 感染发病率的中等到低降低。对 CVE 的监测对于 COVID-19 的预防至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4638/11528902/3c7be5b383ea/2400680-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4638/11528902/aabae806e07f/2400680-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4638/11528902/3c7be5b383ea/2400680-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4638/11528902/aabae806e07f/2400680-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4638/11528902/3c7be5b383ea/2400680-f2.jpg

相似文献

1
Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24.2023 年秋季 COVID-19 疫苗对基于医院的医护人员的有效性:VEBIS 医护人员疫苗有效性队列研究的结果,七个欧洲国家,2023/24 年季节。
Euro Surveill. 2024 Oct;29(44). doi: 10.2807/1560-7917.ES.2024.29.44.2400680.
2
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.2022 年至 2023 年秋冬期间,老年欧洲人群中的 COVID-19 疫苗有效性。
JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258.
3
Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March-December 2021.2021 年 3 月至 12 月期间,格鲁吉亚医护人员的 COVID-19 疫苗初级系列接种有效性。
PLoS One. 2024 Sep 6;19(9):e0307805. doi: 10.1371/journal.pone.0307805. eCollection 2024.
4
Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024.在英国 SIREN 医护人员队列中,疫苗加强针和既往感染对轻度/无症状和中度 COVID-19 感染的保护作用:2023 年 10 月至 2024 年 3 月。
J Infect. 2024 Nov;89(5):106293. doi: 10.1016/j.jinf.2024.106293. Epub 2024 Sep 27.
5
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.2023 年秋季欧洲开展的 COVID-19 疫苗接种效果:基于 VEBIS 初级保健病例对照研究的结果,2023 年 9 月-2024 年 1 月。
Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067. Epub 2024 Jun 4.
6
Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.mRNA 加强针在西班牙巴伦西亚医护人员中预防 SARS-CoV-2 及其主要变异株感染和住院的效果随时间的变化。
Vaccine. 2024 Jul 25;42(19):4011-4021. doi: 10.1016/j.vaccine.2024.05.011. Epub 2024 May 17.
7
Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.新冠病毒加强疫苗接种后医护人员队列的后续严重急性呼吸综合征冠状病毒2血清学研究
BMC Infect Dis. 2024 Apr 24;24(1):436. doi: 10.1186/s12879-024-09338-5.
8
Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy).的里雅斯特教学医院(意大利东北部)医护人员中新冠病毒疫苗突破性感染的风险及相关因素
Viruses. 2022 Feb 7;14(2):336. doi: 10.3390/v14020336.
9
Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.2023 年 10 月至 2024 年 1 月,VEBIS 医院网络,欧洲,针对目标接种人群的 COVID-19 XBB.1.5 疫苗对成人住院的早期有效性。
Influenza Other Respir Viruses. 2024 Aug;18(8):e13360. doi: 10.1111/irv.13360.
10
COVID-19 Immunity in the Cohort of IRCCS San Raffaele Hospital Employees after BNT162b2 Vaccination: A Retrospective Observational Study.辉瑞-BioNTech 疫苗接种后意大利圣拉斐尔医院员工队列的 COVID-19 免疫:一项回顾性观察研究。
Ann Ig. 2024 Jul-Aug;36(4):432-445. doi: 10.7416/ai.2024.2615. Epub 2024 Feb 22.

引用本文的文献

1
Sociodemographic and Occupational Factors Associated With COVID-19 Vaccine and Influenza Vaccine Uptake Among Healthcare Workers, in Albania, 2022-2023: A Multicenter Study.2022 - 2023年阿尔巴尼亚医护人员中与新冠病毒疫苗和流感疫苗接种率相关的社会人口统计学和职业因素:一项多中心研究
Clin Infect Dis. 2025 Aug 1;81(1):30-40. doi: 10.1093/cid/ciaf202.

本文引用的文献

1
Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024.在英国 SIREN 医护人员队列中,疫苗加强针和既往感染对轻度/无症状和中度 COVID-19 感染的保护作用:2023 年 10 月至 2024 年 3 月。
J Infect. 2024 Nov;89(5):106293. doi: 10.1016/j.jinf.2024.106293. Epub 2024 Sep 27.
2
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.2023 年秋季欧洲开展的 COVID-19 疫苗接种效果:基于 VEBIS 初级保健病例对照研究的结果,2023 年 9 月-2024 年 1 月。
Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067. Epub 2024 Jun 4.
3
Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine.2023-2024 年 COVID-19 mRNA 疫苗配方的有效性。
Clin Infect Dis. 2024 Aug 16;79(2):405-411. doi: 10.1093/cid/ciae132.
4
Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024.2023-2024 年(单价 XBB.1.5)更新 COVID-19 疫苗对免疫功能正常成年人中共同流行的奥密克戎变异株引起的有症状 SARS-CoV-2 感染的有效性的早期估计——增加社区获得检测计划,美国,2023 年 9 月至 2024 年 1 月。
MMWR Morb Mortal Wkly Rep. 2024 Feb 1;73(4):77-83. doi: 10.15585/mmwr.mm7304a2.
5
Learning from prepandemic data to forecast viral escape.从大流行前的数据中学习以预测病毒逃逸。
Nature. 2023 Oct;622(7984):818-825. doi: 10.1038/s41586-023-06617-0. Epub 2023 Oct 11.
6
Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.基于遗传距离分析快速评估 COVID-19 疫苗对 SARS-CoV-2 变异株引起的有症状感染的有效性。
Nat Med. 2022 Aug;28(8):1715-1722. doi: 10.1038/s41591-022-01877-1. Epub 2022 Jun 16.